1
|
Deng L, Roose K, Job ER, De Rycke R, Van Hamme E, Gonçalves A, Parthoens E, Cicchelero L, Sanders N, Fiers W, Saelens X. Oral delivery of Escherichia coli persistently infected with M2e-displaying bacteriophages partially protects against influenza A virus. J Control Release 2017; 264:55-65. [PMID: 28842314 DOI: 10.1016/j.jconrel.2017.08.020] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 08/16/2017] [Accepted: 08/18/2017] [Indexed: 01/22/2023]
Abstract
We describe a novel live oral vaccine type. Conceptually, this vaccine is based on a non-lytic, recombinant filamentous bacteriophage that displays an antigen of interest. To provide proof of concept we used the amino-terminal part of a conserved influenza A virus epitope, i.e. matrix protein 2 ectodomain (M2e) residues 2 to 16, as the antigen of interest. Rather than using the phages as purified virus-like particles as a vaccine, these phages were delivered to intestinal Peyer's patches as a live bacterium-phage combination that comprises Escherichia coli cells that conditionally express invasin derived from Yersinia pseudotuberculosis. Invasin-expressing E. coli cells were internalized by mammalian Hep-2 cells in vitro and adhered to mouse intestinal microfold (M) cells ex vivo. Invasin-expressing E. coli cells were permissive for recombinant filamentous bacteriophage f88 that displays M2e and became persistently infected. Oral administration of the live engineered E. coli-invasin-phage combination to mice induced M2e-specific serum IgG antibodies. Mice that had been immunized with invasin-expressing E. coli cells that carried M2e2-16 displaying fd phages seroconverted to M2e and showed partial protection against challenge with influenza A virus. Oral delivery of a live vaccine comprising a bacterial host that is targeted to Peyer's patches and is persistently infected with an antigen-displaying phage, can thus be exploited as an oral vaccine.
Collapse
Affiliation(s)
- Lei Deng
- VIB-UGent Center for Medical Biotechnology, VIB, Technologiepark, 927, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Ghent, Belgium
| | - Kenny Roose
- VIB-UGent Center for Medical Biotechnology, VIB, Technologiepark, 927, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Ghent, Belgium
| | - Emma R Job
- VIB-UGent Center for Medical Biotechnology, VIB, Technologiepark, 927, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Ghent, Belgium
| | - Riet De Rycke
- Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Ghent, Belgium; Inflammation Research Center, VIB, Technologiepark 927, Ghent, Belgium
| | - Evelien Van Hamme
- Inflammation Research Center, VIB, Technologiepark 927, Ghent, Belgium
| | - Amanda Gonçalves
- Inflammation Research Center, VIB, Technologiepark 927, Ghent, Belgium
| | - Eef Parthoens
- Inflammation Research Center, VIB, Technologiepark 927, Ghent, Belgium
| | - Laetitia Cicchelero
- Laboratory of Gene Therapy, Faculty of Veterinary Sciences, Ghent University, Merelbeke, Belgium
| | - Niek Sanders
- Laboratory of Gene Therapy, Faculty of Veterinary Sciences, Ghent University, Merelbeke, Belgium
| | - Walter Fiers
- VIB-UGent Center for Medical Biotechnology, VIB, Technologiepark, 927, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Ghent, Belgium.
| | - Xavier Saelens
- VIB-UGent Center for Medical Biotechnology, VIB, Technologiepark, 927, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Ghent, Belgium.
| |
Collapse
|
2
|
Pakharukova N, Roy S, Tuittila M, Rahman MM, Paavilainen S, Ingars AK, Skaldin M, Lamminmäki U, Härd T, Teneberg S, Zavialov AV. Structural basis for Myf and Psa fimbriae-mediated tropism of pathogenic strains of Yersinia for host tissues. Mol Microbiol 2016; 102:593-610. [PMID: 27507539 DOI: 10.1111/mmi.13481] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/09/2016] [Indexed: 02/06/2023]
Abstract
Three pathogenic species of the genus Yersinia assemble adhesive fimbriae via the FGL-chaperone/usher pathway. Closely related Y. pestis and Y. pseudotuberculosis elaborate the pH6 antigen (Psa), which mediates bacterial attachment to alveolar cells of the lung. Y. enterocolitica, instead, assembles the homologous fimbriae Myf of unknown function. Here, we discovered that Myf, like Psa, specifically recognizes β1-3- or β1-4-linked galactose in glycosphingolipids, but completely lacks affinity for phosphatidylcholine, the main receptor for Psa in alveolar cells. The crystal structure of a subunit of Psa (PsaA) complexed with choline together with mutagenesis experiments revealed that PsaA has four phosphatidylcholine binding pockets that enable super-high-avidity binding of Psa-fibres to cell membranes. The pockets are arranged as six tyrosine residues, which are all missing in the MyfA subunit of Myf. Conversely, the crystal structure of the MyfA-galactose complex revealed that the galactose-binding site is more extended in MyfA, enabling tighter binding to lactosyl moieties. Our results suggest that during evolution, Psa has acquired a tyrosine-rich surface that enables it to bind to phosphatidylcholine and mediate adhesion of Y. pestis/pseudotuberculosis to alveolar cells, whereas Myf has specialized as a carbohydrate-binding adhesin, facilitating the attachment of Y. enterocolitica to intestinal cells.
Collapse
Affiliation(s)
- Natalia Pakharukova
- Department of Chemistry, University of Turku, Turku, Joint Biotechnology Laboratory, Arcanum, Vatselankatu 2, Turku, 20500, Finland
| | - Saumendra Roy
- Department of Chemistry, University of Turku, Turku, Joint Biotechnology Laboratory, Arcanum, Vatselankatu 2, Turku, 20500, Finland.,Department of Chemistry and Biotechnology, Swedish University of Agricultural Sciences, Uppsala BioCentre, P.O. BOX 7016, Uppsala, 75007, Sweden
| | - Minna Tuittila
- Department of Chemistry, University of Turku, Turku, Joint Biotechnology Laboratory, Arcanum, Vatselankatu 2, Turku, 20500, Finland
| | - Mohammad M Rahman
- Department of Chemistry, University of Turku, Turku, Joint Biotechnology Laboratory, Arcanum, Vatselankatu 2, Turku, 20500, Finland
| | - Sari Paavilainen
- Department of Chemistry, University of Turku, Turku, Joint Biotechnology Laboratory, Arcanum, Vatselankatu 2, Turku, 20500, Finland
| | - Anna-Karin Ingars
- Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, P.O. BOX 440, Göteborg, 40530, Sweden
| | - Maksym Skaldin
- Department of Chemistry, University of Turku, Turku, Joint Biotechnology Laboratory, Arcanum, Vatselankatu 2, Turku, 20500, Finland.,Department of Biochemistry/Biotechnology, University of Turku, Tykistökatu 6A, Turku, 20014, Finland
| | - Urpo Lamminmäki
- Department of Biochemistry/Biotechnology, University of Turku, Tykistökatu 6A, Turku, 20014, Finland
| | - Torleif Härd
- Department of Chemistry and Biotechnology, Swedish University of Agricultural Sciences, Uppsala BioCentre, P.O. BOX 7016, Uppsala, 75007, Sweden
| | - Susann Teneberg
- Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, P.O. BOX 440, Göteborg, 40530, Sweden
| | - Anton V Zavialov
- Department of Chemistry, University of Turku, Turku, Joint Biotechnology Laboratory, Arcanum, Vatselankatu 2, Turku, 20500, Finland.,Department of Chemistry and Biotechnology, Swedish University of Agricultural Sciences, Uppsala BioCentre, P.O. BOX 7016, Uppsala, 75007, Sweden
| |
Collapse
|
3
|
Zhang L, Mei M, Yu C, Shen W, Ma L, He J, Yi L. The Functions of Effector Proteins in Yersinia Virulence. Pol J Microbiol 2016; 65:5-12. [PMID: 27281989 DOI: 10.5604/17331331.1197324] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Yersinia species are bacterial pathogens that can cause plague and intestinal diseases after invading into human cells through the Three Secretion System (TTSS). The effect of pathogenesis is mediated by Yersinia outer proteins (Yop) and manifested as down-regulation of the cytokine genes expression by inhibiting nuclear factor-κ-gene binding (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. In addition, its pathogenesis can also manipulate the disorder of host innate immune system and cell death such as apoptosis, pyroptosis, and autophagy. Among the Yersinia effector proteins, YopB and YopD assist the injection of other virulence effectors into the host cytoplasm, while YopE, YopH, YopJ, YopO, and YopT target on disrupting host cell signaling pathways in the host cytosols. Many efforts have been applied to reveal that intracellular proteins such as Rho-GTPase, and transmembrane receptors such as Toll-like receptors (TLRs) both play critical roles in Yersinia pathogenesis, establishing a connection between the pathogenic process and the signaling response. This review will mainly focus on how the effector proteins of Yersinia modulate the intrinsic signals in host cells and disturb the innate immunity of hosts through TTSS.
Collapse
|
4
|
Kochut A, Dersch P. Bacterial invasion factors: tools for crossing biological barriers and drug delivery? Eur J Pharm Biopharm 2012. [PMID: 23207324 DOI: 10.1016/j.ejpb.2012.11.013] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The oral route is the preferential route of drug delivery in humans. However, effective delivery through the gastrointestinal tract is often hampered by the low permeability of the intestinal epithelium. One possibility to overcome this problem is the encapsulation of drugs inside nanoparticulate systems, containing targeting moieties with cell invasive properties. The bioinvasive features of the delivery system could be provided by the attachment of bacterial invasion factors, which promote efficient uptake into host cells and mediate rapid transcytosis of the pathogen through the intestinal epithelium. This review gives an overview of bacterial invasion systems. The molecular structure and function of suitable bacterial invasins, their relative values as targeting agents and possible pitfalls of their use are described. The potential of bioinvasive drug delivery systems is mainly presented on the basis of the well-characterized Yersinia invasin protein, which enters M cells to gain access to subepithelial layers of the gastrointestinal tract, but alternative approaches and future prospects for oral drug delivery are also discussed.
Collapse
Affiliation(s)
- Annika Kochut
- Department of Molecular Infection Biology, Helmholtz Center for Infection Research, Braunschweig, Germany
| | | |
Collapse
|